Akshay Bagai




Please note Dr. Bagai will not be taking any summer students.

Dr. Akshay Bagai is a practicing interventional cardiologist at St. Michael’s Hospital and an Assistant Professor in the Department of Medicine at the University of Toronto. Dr. Bagai received his MD and trained in Internal Medicine and Cardiology at the University of Toronto. He completed his training in Interventional Cardiology at St. Michael’s Hospital.  He obtained a Masters degree in Health Sciences from the Clinical Research Training Program at Duke University, USA. He returned to Toronto and joined the Division of Cardiology at St. Michael’s Hospital in August 2014. His clinical and research interests are closely aligned and include systems of care for acute coronary syndrome and out-of hospital cardiac arrest, adjunctive therapy in coronary syndromes and percutaneous coronary intervention, and revascularization strategies in acute and stable coronary disease.

Recent Publications

  1. Cheema, AN, Yanagawa, B, Verma, S, Bagai, A, Liu, S. Myocardial infarction with nonobstructive coronary artery disease (MINOCA): a review of pathophysiology and management. Curr Opin Cardiol. 2021;36 (5):589-596. doi: 10.1097/HCO.0000000000000886. PubMed PMID:34397465 .
  2. Schwartz, GG, Szarek, M, Bittner, VA, Diaz, R, Goodman, SG, Jukema, JW et al.. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol. 2021;78 (5):421-433. doi: 10.1016/j.jacc.2021.04.102. PubMed PMID:34325831 .
  3. Khan, R, Kaul, P, Islam, S, Savu, A, Bagai, A, van Diepen, S et al.. Drug Adherence and Long-Term Outcomes in Non-Revascularized Patients Following Acute Myocardial Infarction. Am J Cardiol. 2021;152 :49-56. doi: 10.1016/j.amjcard.2021.04.031. PubMed PMID:34120704 .
  4. Patel, A, Goodman, SG, Tan, M, Suskin, N, McKelvie, R, Mathew, AL et al.. Contemporary use of guideline-based higher potency P2Y12 receptor inhibitor therapy in patients with moderate-to-high risk non-ST-segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross-sectional study. Clin Cardiol. 2021;44 (6):839-847. doi: 10.1002/clc.23618. PubMed PMID:33982795 PubMed Central PMC8207978.
  5. Schwartz, GG, Szarek, M, Bittner, VA, Bhatt, DL, Diaz, R, Goodman, SG et al.. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care. 2021;44 (5):1219-1227. doi: 10.2337/dc20-2842. PubMed PMID:33722880 PubMed Central PMC8132323.
  6. Bui, KA, Matteau, A, Elbarouni, B, Bainey, KR, Fordyce, CB, Bagai, A et al.. Management of Acute Coronary Syndromes Beyond the First Year: A Canadian Clinical Practice Survey. CJC Open. 2020;2 (6):619-624. doi: 10.1016/j.cjco.2020.08.002. PubMed PMID:33305222 PubMed Central PMC7710997.
  7. Chaitman, BR, Alexander, KP, Cyr, DD, Berger, JS, Reynolds, HR, Bangalore, S et al.. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. Circulation. 2021;143 (8):790-804. doi: 10.1161/CIRCULATIONAHA.120.047987. PubMed PMID:33267610 PubMed Central PMC7902479.
  8. Dhoot, A, Liu, S, Savu, A, Cheema, ZM, Welsh, RC, Bainey, KR et al.. Cardiac Stress Testing After Coronary Revascularization. Am J Cardiol. 2020;136 :9-14. doi: 10.1016/j.amjcard.2020.08.051. PubMed PMID:32946857 .
  9. Sheth, T, Pinilla-Echeverri, N, Moreno, R, Wang, J, Wood, DA, Storey, RF et al.. Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. J Am Coll Cardiol. 2020;76 (11):1277-1286. doi: 10.1016/j.jacc.2020.07.034. PubMed PMID:32912441 .
Search PubMed

Affiliations & Other Activities

  • Scientist, Heart & Stroke / Richard Lewar Centre of Excellence in Cardiovascular Research